Abstract: A therapeutic agent capable of binding to the receptor CLPTM1 at the surface of an immune cell and modulating its activity for use in modulating the activity of the immune system to treat cancer, wherein the therapeutic agent is capable of inhibiting the growth and/or viability of an anti-inflammatory and/or immunosuppressive cell to relieve unwanted or deleterious immunosuppression by eliminating anti-inflammatory and/or immunosuppressive immune cells; and/or the therapeutic agent is capable of stimulating an antigen-presenting immune cell and acts to stimulate antigen-presenting immune cells to activate an anti-cancer immune response.

Abstract: The invention relates to apolypeptide capable of binding to TGF-? for use in treating or preventing a condition associated with elevated or unwanted levels of TGF-?, wherein said polypeptide is capable of inhibiting the interaction of TGF-? with the receptor CLPTM1.

Abstract: A therapeutic agent capable of binding to the receptor CLPTM1 at the surface of an immune cell and modulating its activity for use in modulating the activity of the immune system to treat cancer, wherein the therapeutic agent is capable of inhibiting the growth and/or viability of an anti-inflammatory and/or immunosuppressive cell to relieve unwanted or deleterious immunosuppression by eliminating anti-inflammatory and/or immunosuppressive immune cells; and/or the therapeutic agent is capable of stimulating an antigen-presenting immune cell and acts to stimulate antigen-presenting immune cells to activate an anti-cancer immune response.

Abstract: The invention relates to apolypeptide capable of binding to TGF-? for use in treating or preventing a condition associated with elevated or unwanted levels of TGF-?, wherein said polypeptide is capable of inhibiting the interaction of TGF-? with the receptor CLPTM1.

Abstract: The present invention providesabinding agent capable of binding to the extracellular domain of CLPTM1 for use in the treatment or prevention of a condition which is responsive to, or benefits from, (i) immunosuppression, (ii) the reduction or reversal of one or more pro-inflammatory cytokines or the induction of an anti-inflammatory cytokine), (iii) an increase in insulin sensitivity, or (iv) therapy with GDF15 and/or TGF-? and/or IFN?, wherein said binding agent has an EC 50 value of 1 ?g/ml or less when determined by measuring binding to membrane-permeabilised O-876 cells expressing native CLPTM1 by flow cytometry, and wherein said binding agent is not a natural ligand for CLPTM.

Abstract: The present invention relates to agents for reducing the activity of GDF15 and in particular the use of such agents to treat or prevent conditions associated with elevated or unwanted levels of GDF15. The invention is based on the discovery that GDF15 binds to the receptors CLPTM1 and QRFPR and provides agents for such use in the form of binding agents capable of binding to the receptors and inhibiting the interaction between GDF15 and the receptor. Further agents include polypeptides derived from the receptors which are capable of binding to GDF15 and inhibiting its interaction with the receptors. Also provided are diagnostic methods based on detecting the interaction or an effect thereof, and cytotoxic immune cells modified to have a reduced level and/or activity of CLPTM1.